
LX7101
CAS No. 1192189-69-7
LX7101( LX-7101 )
Catalog No. M10664 CAS No. 1192189-69-7
LX7101 is a potent, dual LIMK and ROCK inhibitor with IC50 of 4.3/32//69/32/ nM for LIMK2/LIMK1/ROCK1/ROCK2, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
50MG | 897 | Get Quote |
![]() ![]() |
100MG | 1638 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameLX7101
-
NoteResearch use only, not for human use.
-
Brief DescriptionLX7101 is a potent, dual LIMK and ROCK inhibitor with IC50 of 4.3/32//69/32/ nM for LIMK2/LIMK1/ROCK1/ROCK2, respectively.
-
DescriptionLX7101 is a potent, dual LIMK and ROCK inhibitor with IC50 of 4.3/32//69/32/ nM for LIMK2/LIMK1/ROCK1/ROCK2, respectively; kinase selectivity are eveluated in a panel of binding assays including 78 different receptors and transporters at Cerep (only 5 have >60% inhibition at 10 uM); demonstrates high efficacy in mouse model of ocular hypertension, ans shows potential for the treatment of glaucoma.Other Indication Phase 2 Clinical.
-
In VitroLX7101 is a dual LIM-kinase and ROCK inhibitor for the treatment of ocular hypertension and associated glaucoma. LX-7101 also displays potent inhibition of Akt1 with an IC50 of less than 1 nM. The overall selectivity of LX7101 for LIMK2 increases at the higher physiological ATP concentrations. Under physiological conditions, the activity of LX7101 is primarily due to inhibition of LIMK2.
-
In VivoLX-7101 is advanced to Phase-I clinical trials as an intraocular pressure (IOP)-lowering agent for treatment of glaucoma. LX-7101 displays a significant IOP reduction at time points ranging from 1 h to 6 h post administration in rabbits. Topical doses of LX-7101 are evaluated for tolerability on the eyes of mice, rats, and rabbits. It is well tolerated at doses up to 0.5% in non-GLP single dose studies. In the mouse IOP assay, LX-7101 (5%) achieved additional reduction of IOP (5.0 mmHg total reduction) compared to the 0.1% formulation and demonstrated a long duration of action, with IOP not returning to baseline until more than 8 h postdose.
-
SynonymsLX-7101
-
PathwayCell Cycle/DNA Damage
-
TargetLIM Kinase (LIMK)
-
RecptorLIM Kinase (LIMK)
-
Research AreaOther Indications
-
IndicationOther Disease
Chemical Information
-
CAS Number1192189-69-7
-
Formula Weight451.5215
-
Molecular FormulaC23H29N7O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 24 mg/mL
-
SMILESO=C(OC1=CC=CC(NC(C2(CN)CCN(C3=C4C(NC=C4C)=NC=N3)CC2)=O)=C1)N(C)C.[H]Cl
-
Chemical NameCarbamic acid, N,N-dimethyl-, 3-[[[4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]carbonyl]amino]phenyl ester
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Harrison BA, et al. ACS Med Chem Lett. 2014 Nov 24;6(1):84-8.
molnova catalog



related products
-
R-10015
R-10015 is a potent and selective inhibitor of LIM domain kinase (LIMK) and binds to the ATP-binding pocket(IC50 of 38 nM for human LIMK1),and a broad-spectrum antiviral compound for HIV infection.R10015 as a lead compound that blocks LIMK activity by binding to the ATP-binding pocket.?
-
HAMNO
HAMNO is a protein interaction inhibitor of replication protein A (RPA).
-
TH 257
TH 257 is a Potent and selective allosteric LIMK 1/2 inhibitor(LIMK1 and LIMK2 IC50 of 84 nM and 39 nM).